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haBACKGROUND Randomized controlled trials comparing short- (#6 months) with long-term ($1 year) dual antiplatelet
therapy (DAPT) after drug-eluting stent(s) (DES) placement have been insufﬁciently powered to detect signiﬁcant
differences in the risk of major adverse cardiac events (MACE).
OBJECTIVES This study sought to compare clinical outcomes between short- (#6 months) and long-term (1 year)
DAPT and among 3 months, 6 months, and 1 year of DAPT post-DES placement by performing an individual patient data
pairwise and network meta-analysis.
METHODS Randomized controlled trials comparing DAPT durations after DES placement were searched through the
MEDLINE, EMBASE, and Cochrane databases and in international meeting proceedings. The primary study outcome
was 1-year risk of MACE (cardiac death, myocardial infarction, or deﬁnite/probable stent thrombosis).
RESULTS Four trials including 8,180 randomized patients were identiﬁed. At 1-year follow-up, short-term DAPT was
associated with similar rates of MACE (hazard ratio [HR]: 1.11; 95% conﬁdence interval [CI]: 0.86 to 1.43; p ¼ 0.44), but
signiﬁcantly lower rates of bleeding (HR: 0.66; 95% CI: 0.46 to 0.94; p ¼ 0.03) versus prolonged DAPT. Comparable
results were apparent in the landmark period between DAPT discontinuation and 1-year follow-up (for MACE: HR: 1.20;
95% CI: 0.77 to 1.89; p ¼ 0.42) (for bleeding: HR: 0.44; 95% CI: 0.21 to 0.91; p ¼ 0.03). There were no signiﬁcant
differences in 1-year rates of MACE among 3-month versus 1-year DAPT, 6-month versus 1-year DAPT, or 3-month versus
6-month DAPT.
CONCLUSIONS Compared with prolonged DAPT, short-term DAPT is associated with similar rates of MACE but lower
rates of bleeding after DES placement. (J Am Coll Cardiol 2015;65:1092–102) © 2015 by the American College of
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AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome(s)
CI = conﬁdence interval
CrI = credible interval
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
HR = hazard ratio
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
OR = odds ratio
PCI = percutaneous coronary
intervention
PES = paclitaxel-eluting
stent(s)
RCT = randomized clinical trials
ST = stent thrombosis
J A C C V O L . 6 5 , N O . 1 1 , 2 0 1 5 Palmerini et al.
M A R C H 2 4 , 2 0 1 5 : 1 0 9 2 – 1 0 2 DAPT Duration After DES
1093T he optimal duration of dual antiplatelet ther-apy (DAPT) with aspirin and a P2Y12 inhibitorafter drug-eluting stent(s) (DES) implan-
tation remains a matter of debate. Despite de-
monstration of improved efﬁcacy, ﬁrst-generation
sirolimus-eluting stents and paclitaxel-eluting stent(s)
(PES) result in greater rates of very late stent throm-
bosis (ST) and adverse cardiac events compared with
bare-metal stents (1,2). Based on pathological ﬁndings
showing delayed arterial endothelialization after
sirolimus-eluting stents and PES implantation (3,4),
as well as clinical retrospective studies suggest-
ing higher rates of ST with ﬁrst-generation DES
versus bare-metal stents at time of DAPT discontinu-
ation (5,6), the American College of Cardiology/
American Heart Association guidelines extended the
duration of DAPT from 3 months after sirolimus-
eluting stents and 6 months after PES placement
(per randomized clinical trials [RCT]) to at least
1 year (7). Thus, 1 year of DAPT has become the stan-
dard of care worldwide for patients receiving DES,
irrespective of DES type and despite the absence of
evidence-based RCT results.SEE PAGE 1103Because prolonged DAPT is associated with in-
creased bleeding and health care costs (8), estab-
lishing optimal DAPT duration is of paramount
importance. Yet observational studies have been
inconsistent; some reports suggest increased rates
of adverse events in patients with premature DAPT
discontinuation (5,9), whereas others refute this as-
sociation (10,11). Recently, several RCTs failed to
show any beneﬁt of prolonging DAPT ($1 year) versus
a shorter course, challenging the notion that 1 year
of DAPT is necessary after DES implantation (12–16).
However, given the low frequency of adverse events
after DAPT discontinuation, all of these studiesreceived speaker fees from Abbott and Cardiovascular System Inc. Dr. Bhatt
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Manuscript received December 1, 2014; accepted December 18, 2014.were insufﬁciently powered to detect modest
but clinically meaningful differences in
ischemic outcomes. For this reason, we per-
formed an individual patient data meta-
analysis of RCTs investigating the safety and
efﬁcacy of shortening DAPT to <1 year post-
DES implantation.
METHODS
Eligible studies for this meta-analysis were
RCTs comparing short-duration (3 or 6
months) with longer-duration DAPT ($1 year).
Randomized trials comparing 1 year with
>1 year DAPT were excluded. Relevant
RCTs were searched through MEDLINE, the
Cochrane database, the EMBASE database,
www.tctmd.com, www.clinicaltrials.gov, www.
clinicaltrialresults.org, www.cardiosource.com,
and abstracts and presentations from major
cardiovascular meetings, using the keywords
“randomized clinical trial,” “drug-eluting stent,” “dual
antiplatelet therapy,” “clopidogrel,” “aspirin,” and
“thienopyridines.” Two investigators (T.P. and A.M.)
independently reviewed the titles, abstracts, and
studies to determine whether they met the inclusion
criteria. Reviewer conﬂicts were resolved by con-
sensus. No language, publication date, or publication
status restrictions were imposed. The most updated or
inclusive data for a given study were abstracted. In-
ternal validity of RCTs was assessed by evaluating
concealment of allocation, blind adjudication of
events, and inclusion of all randomized patients in the
analysis.
The primary endpoint was the 1-year rate of major
adverse cardiac events (MACE), including the com-
posite of cardiac death, myocardial infarction (MI),
or deﬁnite/probable ST. Secondary pre-speciﬁedis on the advisory board of Elsevier Practice Update
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1094endpoints included the 1-year rates of major and mi-
nor bleeding, cardiac death, all-cause death, MI,
stroke, deﬁnite/probable ST, target vessel revascu-
larization, and combinations of these endpoints. The
endpoint deﬁnitions as applied in each trial were
incorporated. In 3 trials, bleeding was deﬁned ac-
cording to the Thrombolysis In Myocardial Infarction
criteria (13,14,16), whereas in 1 trial, the Randomized
Evaluation of PCI Linking Angiomax to Reduced
Clinical Events criteria were used (12). Patient-level
data were obtained from the principal investigators
of all qualifying trials and combined in a single pooled
database. Frequentist pairwise meta-analysis based
on individual patient data was performed to examine
outcomes between patients treated with short-term
(#6 months) and prolonged (1 year) DAPT (data
beyond 1 year were censored). A network meta-
analysis was performed to compare outcomes of
patients treated with 3-month versus 6-month versus
1-year DAPT (17). From the pooled patient-level
database, we also examined the relative risk of
MACE and bleeding with short-term versus prolonged
DAPT in the following pre-speciﬁed subgroups: age,
sex, diabetes, clinical presentation, multivessel cor-
onary artery disease, and left anterior descending
coronary artery disease. The intention-to-treat popu-
lation was used for these analyses, including all pa-
tients according to randomized treatment arm
regardless of actual treatment. Landmark analyses
were performed at time of DAPT discontinuation using
an “as treated” cohort. For this analysis, patients with
clinical events (death,MI, deﬁnite/probable ST, stroke,
target vessel revascularization, or major bleeding)
occurring before the landmark time point, those with
premature discontinuation of DAPT, and those in
whom DAPT was prolonged $1 month beyond the
period scheduled by randomization were excluded.
Premature discontinuation of DAPT was deﬁned as
DAPT interruption occurring at least 1 month before
the period scheduled by randomization, unless caused
by an adverse event, such as bleeding. ST was deﬁned
according to the Academic Research Consortium
criteria (18). The present review was performed ac-
cording to Preferred Reporting Items for Systematic
Reviews and Meta-Analyses statements (19).
STATISTICAL ANALYSIS. Categorical variables are
reported as count and percentages and compared
with a conditional regression analysis stratiﬁed by
trial. Continuous variables are reported as means
and standard deviation and compared with a 2-way
analysis of variance stratiﬁed by trial. Individual
patient data meta-analysis was performed using a
1-stage approach. Patient data were combined in a
single dataset and ﬁtted in a Cox regression modelstratiﬁed by trial, using trial identiﬁers as random
effects. The proportional assumptions were veriﬁed
using the Schoenfeld residuals. Results are reported
as hazard ratio (HR) with 95% conﬁdence interval (CI)
and as event rates per 1,000 patient-years. To mini-
mize bias, a multivariable Cox regression analysis was
performed, stratiﬁed by trial, and adjusted for a pro-
pensity score determined using a logistic regression
model for treatment with short-term versus pro-
longed DAPT. The following variables were consid-
ered for the propensity score determination: age, sex,
hypertension, dyslipidemia, smoking, diabetes, prior
MI, prior percutaneous coronary intervention (PCI),
prior coronary artery bypass grafting, prior stroke,
clinical presentation, diseased vessels per patient,
type of DES implanted, and number of stents
implanted. The number of patients needed to treat for
an additional beneﬁcial outcome and for an addi-
tional harmful outcome was computed as 1/risk dif-
ference, after imputing risk difference from HR
obtained from Cox proportional hazards analysis
stratiﬁed by trial with random effects and using the
control event rate as reference, including point esti-
mate and 95% CI. The instantaneous risk of MACE or
bleeding for patients on DAPT versus those off DAPT
was determined using kernel hazard functions in the
landmark periods: 91 to 180 days, 181 to 270 days, and
271 to 365 days. Patients were stratiﬁed in these pre-
speciﬁed intervals according to whether they were
on or off DAPT in relation to their treatment assign-
ment, with no crossover between randomization
arms. Patients with clinical events occurring before
the landmark time point were excluded from anal-
ysis, whereas those who prematurely discontinued
DAPT or those who continued DAPT beyond the
period of treatment assignment were censored ac-
cording to their DAPT status. A simple Cox regression
model was used to generate cumulative hazard
function curves of events for each outcome for
descriptive purposes. As a sensitivity analysis, we
performed individual patient data network meta-
analyses within a Bayesian framework with a 2-stage
approach and ﬁxed-effect methods, computing odds
ratios (ORs) and 95% credible intervals (CrIs). Com-
putations were performed with a 100,000-simulation
burn-in phase with inference based on 150,000 sim-
ulations with 3 separate chains.
Extent of small study effects and publication bias
was assessed by visual inspection of funnel plots and
the Egger test. Pairwise inconsistency was assessed
with the I2 statistic, with values <25%, $25%
to #50%, and >50% representing mild, moderate,
and severe heterogeneity, respectively. Values of
p < 0.05 were considered statistically signiﬁcant.
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1095Statistical analyses were performed using STATA
version 12 SE (StataCorp, College Station, Texas) and
WinBUGS 1.4.3 (MRC Biostatistics Unit, Cambridge
University, Cambridge, United Kingdom).
RESULTS
The study analysis ﬂow diagram is shown in Online
Figure 1. Of 911 potentially relevant articles
screened, 4 trials met the inclusion criteria and were
included in the ﬁnal meta-analysis (12–14,16). Among
8,180 randomized patients, 2,622 were randomized to
3 months, 1,473 to 6 months, and 4,085 to at least 1
year of DAPT (including 3,335 to 1 year and 750 to 2
years of DAPT). The major characteristics of the
included trials appear in Table 1. Two studies
compared 3 months with 1 year of DAPT, another 6
months with 1 year of DAPT, and another 6 months
with 2 years of DAPT. For this last trial, PRODIGY
(Prolonging Dual Antiplatelet Treatment After
Grading Stent-Induced Intimal Hyperplasia Study),
the data were censored at 1 year. PRODIGY also
included a quarter of patients randomized to bare-
metal stents at the index intervention; these pa-
tients were excluded to obtain a homogenous DES
population. The major inclusion/exclusion criteria
and internal validity assessment for each trial are
reported in Online Table 1. Clinical, angiographic, and
procedural characteristics of patients stratiﬁed by
treatment are reported in Table 2 for short-term
(#6 month) versus prolonged (1 year) DAPT, and in
Online Table 2 for 3-month versus 6-month versus
1 year DAPT (see Online Table 3 for the deﬁnitions
of each trial’s clinical endpoints).TABLE 1 Main Characteristics of Randomized Trials Included in Meta-
Study (Ref. #) n Primary Endpoint Design
EXCELLENT (13) 6 months
(n ¼ 722)
12 months
(n ¼ 721)
Cardiac death/MI/
ischemia-driven TVR
Noninferiori
OPTIMIZE (12) 3 months
(n ¼ 1,563)
12 months
(n ¼ 1,556)
Death/MI/CVA/major
bleeding
Noninferiori
PRODIGY (16) 6 months
(n ¼ 751)
12 months
(n ¼ 750)
Death/MI/CVA Superiority
RESET (14) 3 months
(n ¼ 1,059)
12 months
(n ¼ 1,058)
Cardiac death/MI/ST/TVR/
major bleeding
Noninferiori
CVA¼ cerebrovascular accident; DAPT¼ dual antiplatelet therapy; EXCELLENT ¼ Efﬁcacy
infarction; OPTIMIZE ¼ Optimized Duration of Clopidogrel Therapy Following Treatme
Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplas
following E-ZES implantation; ST ¼ stent thrombosis; TVR ¼ target vessel revascularizaEstimates of risk and event rates of short- versus
long-term DAPT are shown in Table 3 and Online
Table 4, respectively. At 1-year follow-up, there
was no signiﬁcant difference in the risk of MACE
between treatment groups (HR: 1.11; 95% CI: 0.86 to
1.43; p ¼ 0.44). Conversely, short-term DAPT was
associated with signiﬁcantly lower 1-year rates of
any bleeding compared with prolonged DAPT (HR:
0.66; 95% CI: 0.46 to 0.94; p ¼ 0.03), with a trend
toward lower rates of major bleeding (HR: 0.58; 95%
CI: 0.32 to 1.03; p ¼ 0.06). The number needed to
harm was 46 (95% CI: 65 to 32) for any bleeding and
148 for major bleeding, with an excess of 21 bleeds
and 7 major bleeds for every 1,000 patients treated
with long- rather than short-term DAPT. Results of
short-term versus prolonged DAPT did not signiﬁ-
cantly change after adjusting for the propensity
score (for MACE, adjusted HR: 1.28; 95% CI: 0.79
to 2.04; p ¼ 0.67) (for major bleeding, adjusted
HR: 0.42; 95% CI: 0.20 to 0.89; p ¼ 0.03). Figure 1
shows time-to-event curves for the principal clin-
ical outcomes.
After excluding patients with major events
(n ¼ 258), those lost to follow-up before DAPT inter-
ruption (n ¼ 78), those with premature DAPT
discontinuation (n ¼ 214), and those who continued
DAPT beyond the period of assignment (n ¼ 323),
7,307 patients remained for landmark analyses. Clin-
ical, angiographic, and procedural characteristics of
these patients are presented in Online Table 5 for
short-term (#6 month) versus prolonged (1 year)
DAPT and in Online Table 6 for 3-month versus
6-month versus 1-year DAPT. There were no signiﬁ-
cant differences in MACE rates in the short- versusAnalysis
Follow-Up DAPT Duration (Months) Primary Endpoint Results
ty 1 yr 6 vs. 12 Noninferiority demonstrated
ty 1 yr 3 vs. 12 Noninferiority demonstrated
2 yrs 6 vs. 24 Superiority of 24-month DAPT
not demonstrated
ty 1 yr 3 vs. 12 Noninferiority demonstrated
of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting; MI¼myocardial
nt With the Zotarolimus-Eluting Stent in Real-World Clinical Practice; PRODIGY ¼
ia Study; RESET ¼ REal Safety and Efﬁcacy of a 3-month dual antiplatelet Therapy
tion.
TABLE 2 Baseline Clinical, Angiographic, and Procedural Patient Characteristics
Short DAPT
(#6 Months)
Long DAPT
(1 Year) p Value
Age, yrs 63.1  10.5 63.1  10.7 0.90
Male 66.5% (2,725/4,095) 66.0% (2,696/4,085) 0.61
Hypertension 74.5% (3,052/4,094) 75.9% (3,098/4,084) 0.15
Diabetes mellitus 31.1% (1,274/4,095) 31.2% (1,274/4,085) 0.85
Hypercholesterolemia 62.2% (2,513/4,039) 63.9% (2,570/4,024) 0.12
Smoking 29.4% (944/3,210) 25.5% (858/3,362) 0.04
Prior myocardial infarction 20.5% (837/4,090) 20.5% (838/4,085) 0.94
Prior PCI 14.2% (579/4,090) 13.5% (552/4,085) 0.87
Prior CABG 5.1% (209/4,092) 5.9% (241/4,083) 0.11
Prior stroke 3.1% (127/4,083) 2.7% (110/4,074) 0.27
Renal dysfunction* 0.8% (19/2,532) 1.1% (27/2,529) 0.23
Left ventricular ejection <40% 8.6% (298/3,471) 8.1% (280/3,450) 0.47
Clinical presentation 0.90
Stable CAD 51.0% (1,955/3,837) 51.0% (1,943/3,810)
Unstable CAD 29.5% (1,132/3,837) 29.6% (1,128/3,810)
NSTEMI 11.2% (430/3,837) 11.3% (431/3,810)
STEMI within 24 h 6.4% (246/3,837) 6.4% (242/3,810)
STEMI >24 h–7 days 1.9% (74/3,837) 1.7% (66/3,810)
Discharge medication
Aspirin 99.9% (3,301/3,304) 99.7% (3,280/3,291) 0.05
Clopidogrel 99.8% (3,297/3,304) 99.8% (3,285/3,292) 0.99
Beta-blockers 62.9% (2,287/3,304) 70.5% (2,320/3,292) 0.25
ACE inhibitors/ARB 58.9% (1,946/3,304) 58.0% (1,910/3,292) 0.47
Statins 88.0% (2,906/3,304) 86.7% (2,854/3,292) 0.12
Diseased vessels/patient 1.53  0.01 1.55  0.01 0.34
Number of stented vessels/patient 1.22  0.01 1.22  0.01 0.85
Number of stents/patient 1.61  0.02 1.53  0.01 0.51
Number of lesions stented/patient 1.24  0.01 1.28  0.01 0.37
Total stent length/patient, mm 35.29  0.48 35.83  0.48 0.51
Smallest stent implanted, mm 3.10  0.01 3.10  0.01 0.71
DES type <0.001
PES 6.3% (259/4,087) 6.3% (257/4,083)
SES 4.0% (164/4,087) 12.4% (505/4,083)
CoCr-EES 18.7% (765/4,087) 25.5% (1,042/4,083)
ZES 70.4% (2,878/4,087) 55.1% (2,251/4,083)
Mixed 0.5% (21/4,087) 0.7% (28/4,083)
Stented coronary artery
Left main 2.4% (80/3,374) 2.3% (77/3,367) 0.75
LAD 63.3% (2,419/3,824) 62.7% (2,383/3,800) 0.69
Left circumﬂex 31.4% (1,116/3,557) 32.3% (1,159/3,584) 0.80
Right 36.2% (1,302/3,599) 36.1% (1,290/3,575) 0.88
Bifurcation 15.6% (318/2,036) 16.7% (340/2,034) 0.29
Chronic total occlusion 2.9% (98/3,344) 2.5% (84/3,335) 0.11
Values are mean  SD or % (n/N). *Deﬁned as serum creatinine levels >2 mg/dl.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin-receptor blockade; CABG ¼ coronary artery bypass
grafting; CAD ¼ coronary artery disease; CoCr-EES ¼ cobalt-chromium everolimus-eluting stent(s); DES ¼ drug-
eluting stent(s); LAD ¼ left anterior descending artery; NSTEMI ¼ non ST-segment elevation acute MI; PCI ¼
percutaneous coronary intervention; PES ¼ paclitaxel-eluting stent(s); SES ¼ sirolimus-eluting stent(s); STEMI ¼
ST-segment elevation acute MI; ZES ¼ zotarolimus-eluting stent(s); other abbreviations as in Table 1.
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1096prolonged-treatment groups in the period between
DAPT interruption and 1-year follow-up (HR: 1.20;
95% CI: 0.77 to 1.89; p¼ 0.42) (Table 3, Online Table 4).
In contrast, short-term DAPT was associated with
signiﬁcantly lower rates of major bleeding (HR: 0.30;
95% CI: 0.10 to 0.91; p ¼ 0.03) and any bleeding(HR: 0.44; 95%CI: 0.21 to 0.91; p¼0.03) comparedwith
prolonged DAPT. The number needed to harm was 78
(95% CI: 163 to 37) for any bleeding and 180 (95% CI:
544 to 59) for major bleeding, with an excess of 12
bleeds and 5 major bleeds for every 1,000 patients
treated with long- rather than short-term DAPT.
Results of short-termDAPT versus prolongedDAPTdid
not signiﬁcantly change after propensity adjustment
(for MACE, adjusted HR: 1.28; 95% CI: 0.80 to 2.04;
p ¼ 0.31) (for major bleeding, adjusted HR: 0.28; 95%
CI: 0.07 to 1.10; p ¼ 0.06).
The evidence network appears in Online Figure 2.
No signiﬁcant differences were apparent in the 1-year
rates of MACE between 3- and 6-month DAPT (OR:
0.87; 95% CrI: 0.52 to 1.45), 3-month and 1-year DAPT
(OR: 1.06; 95% CrI: 0.76 to 1.51), or 6-month and
1-year DAPT (OR: 1.23; 95% CrI: 0.84 to 1.82) (Table 4).
In contrast, 6-month DAPT was associated with sig-
niﬁcantly lower rates of major bleeding compared
with 1-year DAPT (OR: 0.38; 95% CrI: 0.14 to 0.95).
No signiﬁcant interactions were apparent between
treatment assignments and pre-speciﬁed patient sub-
groups for risk of MACE at 1 year (Figure 2).
Kernel hazard functions showing the instanta-
neous risk of MACE or bleeding in patients on versus
off DAPT in the landmark periods between 91 and
180 days, 181 and 270 days, or 271 and 365 days are
shown in Figure 3. Although differences were not
statistically signiﬁcant between treatment groups for
any endpoint, MACE rates were numerically lower
and bleeding rates numerically higher for prolonged
DAPT versus short-term DAPT at each landmark in-
terval of time. No statistical heterogeneity was found
for all pairwise analyses. Visual inspection of funnel
plots did not suggest any small study effects or pub-
lication bias (Online Figure 3). The Egger test was
not statistically signiﬁcant (p ¼ 0.10 for 1-year MACE;
p ¼ 0.74 for 1-year major bleeding).
DISCUSSION
This is the largest and most comprehensive report
to date comparing clinical outcomes of short
(#6 months) with prolonged (1 year) DAPT after DES
implantation. The principal ﬁndings are as follows:
1) at 1 year, short-term DAPT was associated with
similar rates of MACE but lower rates of bleeding
compared with prolonged DAPT (Central Illustration);
2) there were no signiﬁcant differences in MACE
rates between treatment groups in the period be-
tween DAPT discontinuation and 1-year follow-up,
but there were lower rates of bleeding with short-
term compared with prolonged DAPT; 3) these re-
sults were consistent across several pre-speciﬁed
TABLE 3 Clinical Outcomes of Short- Versus Long-Term DAPT
Hazard Ratio
(95% CI) p Value
Cumulative events at 1 yr*
Cardiac death, MI, or deﬁnite/probable ST 1.11 (0.85–1.43) 0.44
Cardiac death 0.85 (0.59–1.25) 0.47
All-cause death 0.89 (0.66–1.20) 0.47
MI 1.11 (0.81–1.54) 0.52
Stroke 0.82 (0.55–1.52) 0.53
Deﬁnite/probable ST 1.19 (0.66–2.13) 0.57
Deﬁnite ST 1.14 (0.56–2.33) 0.73
Any bleeding 0.66 (0.46–0.94) 0.02
Major bleeding 0.58 (0.32–1.03) 0.06
Minor bleeding 0.76 (0.50–1.18) 0.22
TVR 1.14 (0.91–1.43) 0.26
Cardiac death, MI 1.08 (0.83–1.41) 0.56
Cardiac death, MI, stroke 1.01 (0.79–1.28) 0.96
Cardiac death, MI, stroke, or major bleeding 0.96 (0.77–1.21) 0.75
All-cause death, MI 1.00 (0.77–1.30) 0.98
All-cause death, MI, stroke 0.95 (0.74–1.22) 0.68
All-cause death, MI, stroke, or major bleeding 0.93 (0.73–1.19) 0.56
Events between DAPT discontinuation and 1 yr†
Cardiac death, MI, or deﬁnite/probable ST 1.21 (0.77–1.89) 0.42
Cardiac death 1.25 (0.71–2.22) 0.43
All-cause death 1.14 (0.73–1.79) 0.58
MI 0.89 (0.47–1.67) 0.70
Stroke 0.74 (0.28–1.92) 0.54
Deﬁnite/probable ST 1.56 (0.44–5.56) 0.49
Deﬁnite ST 1.75 (0.42–7.14) 0.45
Any bleeding 0.44 (0.21–0.91) 0.03
Major bleeding 0.30 (0.10–0.91) 0.03
Minor bleeding 0.73 (0.28–1.92) 0.53
TVR 1.14 (0.86–1.52) 0.39
Cardiac death, MI 1.14 (0.73–1.79) 0.57
Cardiac death, MI, stroke 1.05 (0.69–1.59) 0.81
Cardiac death, MI, stroke, or major bleeding 0.94 (0.64–1.39) 0.76
All-cause death, MI 1.05 (0.69–1.59) 0.82
All-cause death, MI, stroke 1.01 (0.68–1.49) 0.95
All-cause death, MI, stroke, or major bleeding 0.91 (0.62–1.33) 0.63
*Intention-to-treat analysis. †As-treated analysis.
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
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1097subgroups of patients, with no interactions apparent
between treatment assignment and age, sex, dia-
betes, clinical presentation, multivessel, or left ante-
rior descending coronary artery disease; and 4) by
Bayesian network meta-analysis, no signiﬁcant dif-
ferences in 1-year MACE rates were apparent between
3 and 6 months of DAPT, 3 months and 1 year of
DAPT, or 6 months and 1 year of DAPT.
Establishing optimal DAPT duration is critical for
balancing the risks of ischemic and bleeding com-
plications after DES implantation. Acknowledging
the limited statistical power of all current, relevant
RCTs (12,14–16), we performed an individual patient
data pairwise and network meta-analysis, including
8,180 patients receiving various types of ﬁrst- and
second-generation DES who were treated with DAPT
for 3 months, 6 months, or 1 year. At 1-year follow-up,
no signiﬁcant differences in MACE rates were
apparent between treatment groups. In contrast, short-
term DAPT was associated with signiﬁcantly lower
rates of bleeding compared with prolonged DAPT.
Theseﬁndings are of clinical relevance given the strong
association between major bleeding and adverse out-
comes. In numerous studies, bleeding has emerged as
an independent predictor for subsequent mortality in
patients with acute coronary syndrome (ACS) and in
those undergoing PCI, with a hazard equivalent to or
even greater than that for MI (20–22).
One limitation of trials included in this meta-
analysis is that patients were randomized at the
time of PCI (or 1 month post-procedure), before 3- or
6-month planned DAPT discontinuation. Events thus
occurring before DAPT discontinuation would serve
only to dilute differences between treatment arms.
For example, in the EXCELLENT (Efﬁcacy of Xience/
Promus Versus Cypher to Reduce Late Loss After
Stenting) trial, there was a numerically higher risk of
1-year ST with 6 compared with 12 months of DAPT
(13). However, most of this difference accrued in the
ﬁrst 6 months from randomization, when all patients
were on DAPT. Therefore, it is improper to attribute
higher ST risk to the short-term DAPT strategy in this
trial. Moreover, some patients in these trials would
have already stopped DAPT before the planned
randomization time of DAPT discontinuation (e.g.,
for an earlier bleeding episode) or would not be able
to discontinue DAPT after that time period (e.g.,
because of an earlier ST). The ideal study design
would have randomized patients free from MACE and
bleeding at 3 or 6 months to either continue or dis-
continue DAPT, thereby mimicking the clinical deci-
sion that would be made in stable patients. Because
of logistical considerations, none of the trials incor-
porated this optimal design.To address this limitation, we performed a land-
mark analysis of events in the period between DAPT
discontinuation and 1-year follow-up, based on
actual patient DAPT status (“as treated” cohort). We
excluded patients with major events, those lost
to follow-up before the landmark time point of
DAPT discontinuation, those with premature DAPT
discontinuation, and those who continued DAPT
beyond the assigned period (unless caused by an
earlier adverse event). In this landmark analysis,
DAPT discontinuation at 3 or 6 months did not
produce higher rates of MACE compared with DAPT
continuation to 1 year but was associated with
FIGURE 1 Efﬁcacy and Safety Endpoints
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Cumulative hazard curves derived from Cox regression analysis show key efﬁcacy and safety endpoints for short (#6 months) dual antiplatelet therapy (DAPT) versus
prolonged (1 year) DAPT. MI ¼ myocardial infarction; ST ¼ stent thrombosis.
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1098signiﬁcantly lower rates of bleeding, including ma-
jor bleeding, conﬁrming the main results of the
(intention-to-treat) meta-analysis.
By Bayesian network meta-analysis, no signiﬁcant
differences were apparent in MACE rates between 3
and 6 months of DAPT or either of those time periods
versus 1-year DAPT, suggesting that even 3 months of
DAPT may sufﬁce after DES implantation. Impor-
tantly, no signiﬁcant differences in clinical, angio-
graphic, and procedural characteristics were apparent
among patients treated for the periods of DAPT
treatment studied, with DES use the only exception.
The even distribution of most effect modiﬁers across
the 3 treatment groups represents, therefore, an un-
biased basis for indirect comparisons. However,
because of the limited number of studies included,
this analysis was insufﬁciently powered to draw
deﬁnitive conclusions.Moreover, kernel hazard functions implemented in
the landmark periods of 91 to 180 days, 181 to 270 days,
and 271 to 365 days suggest slightly increased rates
of ischemic events in each interval of time in patients
off compared with on DAPT. These differences were
far from being statistically signiﬁcant; thus, whether
these ﬁndings are real or chance remains undeter-
mined. Based on this meta-analysis, we estimated
that 53,656 patients would be necessary to determine
whether the small difference observed between
treatment groups is real, with a ¼ 0.05 and b ¼ 0.90.
Nonetheless, this potential small beneﬁt associated
with prolonged DAPT is clinically more than offset
by this strategy’s increased risk of major bleeding.
Our ﬁndings should be considered in light of
the recently reported DAPT trial in which 9,961 pa-
tients who were event-free 1 year after DES implan-
tation were randomized to continued thienopyridine
TABLE 4 Effect Estimates for Cumulative 1-Year Events
3- vs.
6-Month DAPT
3-Month vs.
1-Year DAPT
6-Month vs.
1-Year DAPT
3- or 6-Month vs.
1-Year DAPT
3- vs. 6-Month
or 1-Year DAPT
Cardiac death, MI, or
deﬁnite/probable ST
0.87 (0.52–1.45) 1.06 (0.76–1.51) 1.24 (0.84–1.82) 1.14 (0.88–1.40) 1.06 (0.75–1.52)
Cardiac death 0.94 (0.45–1.96) 0.84 (0.52–1.41) 0.89 (0.51–1.54) 0.88 (0.61–1.25) 0.85 (0.52–1.41)
All-cause death 1.05 (0.58–1.85) 0.89 (0.59–1.35) 0.85 (0.57–1.28) 0.88 (0.66–1.18) 0.83 (0.59–1.35)
MI 0.88 (0.47–1.67) 1.11 (0.73–1.70) 1.25 (0.77–2.04) 1.16 (0.85–1.59) 1.10 (0.72–1.70)
Stroke 1.92 (0.59–6.25) 1.00 (0.42–2.56) 0.52 (0.23–1.12) 0.70 (0.39–1.21) 0.99 (0.41–2.38)
Deﬁnite or probable ST 0.55 (0.18–1.59) 1.00 (0.49–2.00) 1.82 (0.81–4.17) 1.30 (0.77–2.27) 1.02 (0.49–2.13)
Deﬁnite ST 0.33 (0.07–1.43) 0.64 (0.18–1.89) 1.89 (0.80–4.76) 1.25 (0.64–2.50) 0.65 (0.21–1.79)
Any bleeding 1.37 (0.66–2.78) 0.75 (0.47–1.08) 0.53 (0.28–0.94) 0.65 (0.45–0.92) 0.71 (0.46–1.08)
Major bleeding 1.70 (0.54–5.88) 0.66 (0.31–1.39) 0.38 (0.14–0.95) 0.52 (0.30–0.93) 0.66 (0.31–1.39)
Minor bleeding 1.11 (0.42–3.03) 0.78 (0.48–1.28) 0.69 (0.30–1.64) 0.76 (0.50–1.16) 0.78 (0.47–1.27)
TVR 1.05 (0.67–1.67) 1.22 (0.89–1.67) 1.15 (0.83–1.61) 1.19 (0.95–1.49) 1.22 (0.89–1.67)
Cardiac death, MI 0.93 (0.54–1.59) 1.08 (0.75–1.54) 1.16 (0.79–1.72) 1.11 (0.86–1.45) 1.06 (0.75–1.52)
Cardiac death, MI, or stroke 1.06 (0.66–1.72) 1.06 (0.76–1.47) 1.00 (0.70–1.41) 1.03 (0.81–1.32) 1.06 (0.76–1.47)
Cardiac death, MI, stroke,
or major bleeding
1.00 (0.63–1.59) 0.96 (0.71–1.30) 0.95 (0.68–1.35) 0.95 (0.76–1.20) 0.95 (0.70–1.30)
All-cause death, MI 0.98 (0.61–1.56) 1.03 (0.75–1.43) 1.05 (0.75–1.47) 1.05 (0.83–1.33) 1.04 (0.76–1.43)
All-cause death, MI, or stroke 1.12 (0.71–1.72) 1.05 (0.77–1.41) 0.94 (0.68–1.30) 0.99 (0.79–1.23) 1.05 (0.78–1.43)
All-cause death, MI, stroke,
or major bleeding
1.02 (0.66–1.59) 0.94 (0.69–1.25) 0.91 (0.66–1.25) 0.93 (0.75–1.14) 1.06 (0.75–1.52)
Estimates of risk are reported as odds ratio and 95% credible interval. Statistically signiﬁcant differences are highlighted in bold.
Abbreviations as in Table 1.
FIGURE 2 Patient Subgroups and DAPT Duration
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Interaction is analyzed between various pre-speciﬁed subgroups of patients and DAPT
duration; the hazard ratio (HR) and 95% conﬁdence interval (CI) are for the composite of
cardiac death, MI, or ST. ACS ¼ acute coronary syndrome(s); LAD ¼ left anterior
descending; MVD ¼ multivessel disease; other abbreviations as in Figure 1.
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1099treatment or placebo for another 18 months (23). In
that trial, prolonged DAPT signiﬁcantly reduced the
risk of ST and MACE compared with aspirin only,
albeit with increased bleeding. All-cause mortality
was increased in the prolonged DAPT arm, which may
or may not have been caused by chance. Importantly,
the subgroup analysis of patients with versus without
ACS has not been reported. ST risk in the DAPT trial
between 1 and 2.5 years after DES implantation was
1.4% in control subjects (higher than expected from
prior large-scale studies) (24), driven by especially
high rates in patients receiving PES. Among patients
treated with everolimus-eluting stents in DAPT,
the absolute reduction in ST with prolonged DAPT was
only 0.4% with no signiﬁcant difference in MACE
(although bleeding still increased). In contrast, our
results are consistent with the recently reported ISAR-
SAFE (Intracoronary Stenting and Antithrombotic
Regimen: Safety and Efﬁcacy of 6 Months Dual Anti-
platelet Therapy After Drug-Eluting Stenting) and
ITALIC (Is There A Life for DES after Discontinuation of
Clopidogrel) results, which showed no additional
beneﬁts of prolonging DAPT from 6 to either 12 or 24
months, respectively, with contemporary DES (25,26).
Thus, the optimal duration of DAPT after DES implan-
tation may vary in relation to patient characteristics
and stent type, suggesting that ongoing risk of
ischemia versus bleeding should be considered for
each patient when determining DAPT duration.
FIGURE 3 Event and Bleeding Risk by Kernel Hazard Function
p = 0.315
p = 0.380
M
aj
or
 B
le
ed
in
g
An
y 
Bl
ee
di
ng
Ca
rd
ia
c 
De
at
h,
 M
I, 
ST p = 0.236
p = 0.080
p = 0.093
p = 0.809
p = 0.343
p = 0.099
p = 0.831
1.00e-06 5.00e-11
4.00e-11
3.00e-11
2.00e-11
1.00e-11
.000020
.000015
.000010
.000005
.000000
.000020
.000015
.000010
.000005
.00005
.00004
.00003
.00002
.00001
.00000
.000022 .000050
.000045
.000040
.000035
.000030
.000020
.000018
.000016
8.00e-07
6.00e-07
4.00e-07
2.00e-07
1.00e-06
8.00e-07
6.00e-07
4.00e-07
2.00e-07
.00007
.00006
.00005
.00004
.00003
91 120 150
Days Days Days
180 181 210 240 270 271 300 330 365
0
Off DAPT On DAPT
Instantaneous risk of major adverse cardiac events and bleeding were determined by kernel hazard function in patients on DAPT versus those off DAPT
between 91 to 180 days, 181 to 270 days, and 271 to 365 days. No signiﬁcant difference in ischemic events was apparent at any time interval. Abbreviations
as in Figure 1.
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1100Our meta-analysis conﬁrms and extends the results
from previous reports (27–29). However, a major limi-
tation of previous meta-analyses was the inclusion of
trials comparing 1 year with 2 years of DAPT along
with shorter-term DAPT trials; consequently, 1-year
DAPT was considered “prolonged” therapy in some
studies but “short term” in others (27–29). Addition-
ally, trials with heterogeneous study designs were
included, such that in some trials patients were ran-
domized at time of PCI (14–16), whereas in others,
event-free patients at 1 year were considered for
randomization (15). Beyond addressing these draw-
backs, our study’s most unique aspect is the analysis
of patient-level data, allowing adjustments for mea-
sured confounders and the analysis of interaction be-
tween DAPT duration and pre-speciﬁed subgroups of
patients, as well as the crossed comparison among
3 months versus 6 months versus 1 year of DAPT.
STUDY LIMITATIONS. As with any meta-analysis,
our report shares the original studies’ limitations. Pa-
tients included were, in general, at low risk, with the
exception of the PRODIGY trial patients (16).Moreover,most patients were treated with everolimus-eluting
stents or zotarolimus-eluting stents, which have been
associated with low event rates. Nonetheless, with an
observed MACE rate of 3% in the short-term DAPT
group, our study had 90% power to detect a 40%
relative risk reduction in MACE rates in the long-term
DAPT group with a ¼ 0.05. However, the pre-
sent study was underpowered for lower-frequency
event rates, such as ST, for which w50,000 patients
would have been required to demonstrate differences
between groups given the observed event rates.
Furthermore, subgroup analysis is inherently under-
powered and should be considered exploratory and
hypothesis-generating only. The same is true for
landmark analyses. We therefore do not currently
recommend that DAPT be discontinued before 1 year in
high-risk patients, particularly those with troponin-
positive ACS.
Because zotarolimus- and everolimus-eluting stents
were implanted in most patients in the compo-
nent studies, the results of the present meta-analysis
cannot be extrapolated to other types of DES.
CENTRAL ILLUSTRATION Dual Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation
In a meta-analysis of trials considering time on dual antiplatelet therapy (DAPT) after implantation of drug-eluting stents, short-term (#6 months)
pharmacotherapy produced similar rates of major adverse cardiac events (A) but signiﬁcantly less bleeding (B) than longer-term ($1 year) DAPT.
MI ¼ myocardial infarction; ST ¼ stent thrombosis.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In selected pa-
tients, a shorter period (3 to 6 months) of DAPT is associated
with similar rates of adverse ischemic events and less major
bleeding than treatment for 1 year, improving net clinical patient
outcomes after DES deployment.
TRANSLATIONAL OUTLOOK: Further studies are needed to
deﬁne the characteristics of patients who beneﬁt from shorter or
longer periods of DAPT after DES implantation.
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1101Additionally, any possible interaction between DES
type and DAPT duration, as suggested by some studies
(30), cannot be excluded and deserves further
investigation.
All trials included in the meta-analysis were open
label, potentially introducing performance bias. Deﬁ-
nitions of some clinical endpoints differed slightly
across trials, potentially introducing effect modiﬁers.
All patients included in themeta-analysis were treated
with clopidogrel as adjunctive therapy to aspirin. It
remains undetermined whether results would have
differed with the newer, more potent antiplatelet
drugs prasugrel and ticagrelor, which is most relevant
in patients with ACS. Therewere few bleeds in patients
treated with 3 or 6 months of DAPT, making our ana-
lyses insufﬁciently powered to determine potential
differences between these 2 strategies. Finally, few
patients with renal dysfunction were enrolled in the
included clinical trials; therefore, we could not assess
this variable’s impact as a possible effect modiﬁer.
CONCLUSIONS
In a meta-analysis of 8,180 patients treated with DES,
short-term DAPT was associated with similar rates of
MACE but lower rates of bleeding compared with
prolonged DAPT. These data suggest that a short-term
DAPT strategy is appropriate for selected patientspost-DES in the contemporary era, especially those
without high-risk clinical or lesion characteristics.
The decision to use short-term DAPT should also be
conditioned on the individual risk (and likely impact)
of ischemic versus bleeding complications for each
patient. Additional study is required to determine
whether 3 or 6 months of DAPT is preferred in pa-
tients for whom an abbreviated regimen is chosen.
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